Medivation has 'best-in-class' ambitions for newly purchased PARP inhibitor

Medivation ($MDVN) made a name for itself with Xtandi, the prostate cancer med that's now giving Johnson & Johnson's ($JNJ) Zytiga a run for its money. Now, it wants to challenge other drugmakers in the PARP inhibitor field, too. And as analysts point out, Medivation thinks the PARP med it picked up from BioMarin ($BMRN) this week could be a "best-in-class" performer. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.